Dr Lal Pathlabs
Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%
Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.
 "Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%")
Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive
Dr. Lal PathLabs recorded a 16.6 per cent Y-o-Y rise in revenue from operations to ₹702 crore in Q4 FY26 from ₹659.8 crore in the year-ago period
 "Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive")
Dr Lal PathLabs Q4FY26 results: Net profit falls 15%; revenue rises 16.6%
Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix
 "Dr Lal PathLabs Q4FY26 results: Net profit falls 15%; revenue rises 16.6%")
Dr Lal Path Labs Q4 FY26 results: Profit down 15.5%, revenue up 16.6%
Consolidated net profit fell to 1.31 billion rupees ($13.8 million) in the quarter ended March, from 1.55 billion rupees a year earlier
Dr Lal back on the acquisition trail, tests South India for opportunities
After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions
 "Dr Lal back on the acquisition trail, tests South India for opportunities")
Dr Lal back on the acquisition trail, tests South India for opportunities
After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions
Dr Lal PathLabs Q3 net profit falls 6.4% on new labour code impact
Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion
Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes
The country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes
Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes
The country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes
HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target
Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares
 "HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target")
Preventive, precision testing spurs a bigger dose of diagnostics chains
Diagnostic chains are expanding laboratories, integrated centres and collection networks as demand grows for preventive, genomics-led and precision testing across India
 "Preventive, precision testing spurs a bigger dose of diagnostics chains")
Stocks gaining momentum? Here's why Escorts, Hudco, 3 others are on radar
Technical charts show Escorts, Hudco, Dr Lal PathLabs, Force Motors and Godrej Consumer were trading above the higher-end of the Bollinger Bands on the daily scale; and can potentially rally up to 23%
 "Stocks gaining momentum? Here's why Escorts, Hudco, 3 others are on radar")
Dr Lal PathLabs Q2 results: PAT up 16.4% at ₹152 crore, revenue rises 11%
Diagnostics chain declares ₹7 per share interim dividend, 1:1 bonus issue
 "Dr Lal PathLabs Q2 results: PAT up 16.4% at ₹152 crore, revenue rises 11%")
Will Apollo, Max, Metropolis outshine peers in Q2? Here's what analysts say
Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.
 "Will Apollo, Max, Metropolis outshine peers in Q2? Here's what analysts say")
Dr. Lal Path Labs rises 3% on adopting new AI cancer diagnostic tool
Dr. Lal Path Labs shares rose 3.2 per cent on Wednesday, after it became the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastas
 "Dr. Lal Path Labs rises 3% on adopting new AI cancer diagnostic tool")
Dividend, bonus, rights issue, demerger: BoB, Concor & 23 others in focus
Bank of Baroda, Concor, HDFC Asset Management Company, and 22 others will be in focus today as they will trade ex-date on Friday, June 6, 2025
 "Dividend, bonus, rights issue, demerger: BoB, Concor & 23 others in focus")
These 5 pharma stocks can fall up to 12% as technical charts flag caution
Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.
 "These 5 pharma stocks can fall up to 12% as technical charts flag caution")
Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion
The company's revenue from operations also rose to Rs 603 crore in Q4FY25, a 10.5 per cent Y-o-Y growth from Rs 545 crore reported in Q4FY24
Dr Lal Path Labs Q4FY25 results: Net profit rises 83.2% to ₹155 crore
The company's consolidated net profit jumped 83.2 per cent year-on-year to Rs 1.55 billion (about $18 million) in the quarter ended March 31
Dr Lal Q3FY25 results: PAT jumps 19% to Rs 98 crore as volumes grow
As for Suburban Diagnostics, an arm of Dr Lal Pathlabs, revenue growth was 9.2 per cent in Q3